New immune therapy trial offers hope for advanced liver cancer patients
NCT ID NCT05033522
Summary
This study tests whether an immunotherapy called AlloStim can help people with advanced liver cancer live longer and feel better than current standard treatments. The trial involves 150 Asian adults with advanced liver cancer who haven't had previous treatment for their advanced disease. Participants are randomly assigned to receive either AlloStim immunotherapy or one of three standard drug treatments chosen by their doctor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiangmai University
Chiang Mai, Thailand
-
Columbia Asia Bukit Rimau
Shah Alam, Selangor, 40460, Malaysia
-
Naresuan University Hospital
Phitsanulok, Tha Pho, 65000, Thailand
-
Prince of Songkla University (Songklanagarind Hospital)
Hat Yai, Changwat Songkhla, 90110, Thailand
-
Siriraj Hospital
Bangkok Noi, Bangkok, 10700, Thailand
-
Songklanagarind Hospital
Khon Kaen, Thailand
-
Sultan Ismail Hospital
Johor Bahru, Johor, 81100, Malaysia
-
Sultanah Bahiyah Hospital
Alor Star, Kedah, 05460, Malaysia
Conditions
Explore the condition pages connected to this study.